Trial · NCT07896915
A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants
NCT07896915, Phase 1, Active not recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants. Trials, record NCT07896915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896915
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Pharmacokinetic Characteristics of HS-20118 Under Different Dosing Conditions in Healthy Participants
- NCT number
- NCT07896915
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 32 participants, actual
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Conditions
- Healthy Participants
- Interventions
- HS-20118, HS-20118
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cmax of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Primary | Tmax of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Primary | AUC0-t of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Primary | AUC0-inf of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Primary | t1/2 of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Primary | CL/F of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Primary | Vd/F of HS-20118 under different administration conditions | Pre-dose up to Day 36 post-dose in Period 1, up to Day 78 in Period 2, up to Day 120 in Period 3, and up to Day 162 in Period 4 | |
| Secondary | Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), and Safety Abnormalities | Day 1 up to Day 183 | Incidence, seriousness, and severity of adverse events will be evaluated. Safety assessments will include vital signs, 12-lead electrocardiogram (ECG) parameters, physical examinations, and clinical laboratory tests. |
| Secondary | Incidence of Anti-drug antibody (ADA) | Pre-dose on Day 1 up to Day 162 | Blood samples will be analyzed for the presence of ADAs against HS-20118 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896915
GET https://conductscience.org/api/trials/v1/NCT07896915/registered